IP Library Granted Patent US 11,484,496
Granted Patent B2
US 11,484,496 · App. 16/857,927 · Granted Nov 1, 2022

Sustained-release 9-cis retinoic acid implantable drug delivery pellets for the prevention of postsurgical edema and lymphedema

Inventors: Alex K. Wong (Los Angeles, CA); Young-Kwon Hong (Pasadena, CA)
Assignee: University of Southern California
A61K9/0024A61K31/203A61K47/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,484,496
App. No.
16/857,927
Granted
Nov 1, 2022
Kind
B2
Abstract

A method of treating post-surgical edema includes a step of administering an effective amount of a pharmaceutical composition to a subject identified a risk of post-surgical edema. The pharmaceutic composition include a retinoic acid component selected from the group consisting of 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof. An implantable pellet including the retinoic acid component is also provided.

Claims (10)

1. A pharmaceutical composition comprising:

a carrier; and

a retinoic acid component dispersed within the carrier in an effective amount to treat postsurgical lymphedema, the pharmaceutical composition being formed into an implantable pellet, the retinoic acid component being selected from the group consisting of 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof.

2. The pharmaceutical composition of claim 1 wherein the retinoic acid component is present in an amount of 0.5 to 30 milligrams.

3. The pharmaceutical composition of claim 1 wherein the carrier is at least partially biodegradable.

4. The pharmaceutical composition of claim 1 wherein the carrier is a biodegradable matrix that effectively and continuously releases 9-cis retinoic acid after implantation in a subject.

5. The pharmaceutical composition of claim 4 at least 90 percent of the retinoic acid component is released into the subject after 60 days post implantation.

6. The pharmaceutical composition of claim 4 wherein the carrier includes cholesterol, lactose, celluloses, phosphates, and stearates.

7. The pharmaceutical composition of claim 1 further comprising one or more diluents, excipients, and carriers.

8. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition is a sustained release formulation.

Assignments (2)
LICENSE Recorded Jul 30, 2024
From: UNIVERSITY OF SOUTHERN CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068202/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2022
From: WONG, ALEX K.; HONG, YOUNG-KWON
To: UNIVERSITY OF SOUTHERN CALIFORNIA
Reel/Frame 060190/0005 →
Continuity (2)
Provisional Application 62838253 · Apr 24, 2019
Related Publication 20200337991A1 · Oct 29, 2020